Summary:
In adults with type 1 diabetes and chronic kidney disease (CKD), finerenone treatment significantly reduced the urinary albumin-to-creatinine ratio compared to placebo, though it was associated with potential side effects related to mineralocorticoid receptor antagonism (such as hyperkalemia).
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 1 diabetes mellitus complicated by chronic kidney disease. |
| Intervention | Administration of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, dosage as per clinical protocol. |
| Comparison | Placebo treatment administered under identical conditions. |
| Outcome | Finerenone significantly reduced urinary albumin-to-creatinine ratio compared to placebo, indicating improved kidney function and reduced disease progression risk; associated adverse effects include hyperkalemia and related mineralocorticoid receptor antagonist side effects. |
Source: Heerspink, Hiddo J L, et al. “Finerenone in Type 1 Diabetes and Chronic Kidney Disease.” Read article here.
